Şunu aradınız:: in locally anchored contexts (İngilizce - Danca)

overall survival in locally advanced disease by therapy sub-group
overlevelse i lokalt avanceret sygdom opdelt efter terapigruppe.

progression-free survival in locally advanced disease by therapy sub-group
progressionsfri overlevelse ved lokal avanceret sygdom, fordelt på behandlingsundergrupper

the precise mechanism of action of vandetanib in locally advanced or metastatic mtc is unknown.
vandetanibs nøjagtige virkningsmekanisme ved lokalt fremskreden eller metastaserende mtc kendes ikke.

table 1 progression-free survival in locally advanced disease by therapy sub-group
tabel 1 progressionsfri overlevelse ved lokalt avanceret sygdom pr. behandlingsundergruppe

it is acknowledged that overall there is no statistically significant survival benefit in locally advanced prostate cancer.
det erkendes, at der totalt ikke er nogen fordel i form af statistisk signifikant længere overlevelse ved lokalt avanceret prostatacancer.

in locally advanced or metastatic breast cancer, xeloda with docetaxel has been compared with docetaxel on its own in 511 women.
med hensyn til lokalt fremskreden eller metastatisk brystkræft er xeloda plus docetaxel blevet sammenlignet med docetaxel alene hos 511 kvinder.

- the lack of an overall survival benefit versus adverse events in ‘ locally advanced prostate cancer’;
- den manglende fordel i total overlevelse, sammenholdt med bivirkningerne, ved "lokal avanceret prosta -

at the time the isd was adopted, exchanges enjoyed a national franchise for the organised matching of buy/sell interests in locally issued securities.
da isd blev vedtaget, havde de nationale børser eneret på den organiserede matchning af interessemarkeringer angående lokalt udstedte værdipapirer.

in conclusion, the heart failure data remain a concern and are inconclusive, but do not significantly alter the benefit/risk balance in locally advanced prostate cancer patients.
som konklusion giver data vedrørende hjertesvigt fortsat anledning til betænkelighed og de er inkonklusive, uden at de dog væsentligt ændrer risk/benefit-forholdet ved lokalt avanceret prostatacancer.disse data støtter

in locally advanced or metastatic breast cancer, xeloda combined with docetaxel was more effective that docetaxel on its own in lengthening the time taken for the disease to progress (186 days compared with 128 days) .
til lokalt fremskreden eller metastatisk brystkræft var xeloda kombineret med docetaxel mere effektivt end docetaxel alene til at forlænge tiden indtil sygdommen skred frem (186 dage mod 128 dage) .

in locally advanced cancer (when the tumour has grown but has not spread), erbitux is given in combination with radiotherapy (treatment with radiation).
ved lokalt fremskreden kræft (hvor tumoren er vokset, men ikke har spredt sig), gives erbitux i kombination med strålebehandling.

combination therapy with xeloda and docetaxel in locally advanced or metastatic breast cancer data from one multicentre, randomised, controlled phase iii clinical trial support the use of xeloda in combination with docetaxel for treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy, including an anthracycline.
kombinationsbehandling med xeloda og docetaxel ved lokal advanceret eller metastatisk brystkræft data fra et randomiseret, kontrolleret, klinisk fase iii- multicenterstudie støtter anvendelsen af xeloda i kombination med docetaxel til behandling af patienter med lokal fremskreden eller metastatisk brystkræft hos hvem cytotoksisk kemoterapi, inklusive et anthracyklin, har svigtet.

in locally recurrent and metastatic breast cancer, grade 3-5 wound healing complications were observed in 1.1% of patients receiving avastin + paclitaxel and in none of the patients receiving paclitaxel alone.
i lokalt recidiverende eller metastatisk brystkræft blev der observeret sårhelingskomplikationer af grad 3-5 observeret hos 1, 1% af patienterne, som fik avastin samt paclitaxel, hvorimod det ikke sås for patienter, som kun modtog paclitaxel.

in locally advanced head and neck cancers, the patients lived for longer without their disease getting worse when erbitux was added to radiotherapy (24.4 months compared with 14.9 months, on average).
ved lokalt fremskreden hoved-hals-kræft levede patienterne længere, uden at sygdommen blev værre, når erbitux blev føjet til strålebehandling (24,4 måneder sammenlignet med 14,9 måneder i gennemsnit).

following their own review of these data carried out in 2004 and due to their resulting concerns over the benefit/ risk balance of bicalutamide 150 mg in locally advanced prostate cancer, the belgian regulatory authority suspended their national marketing authorisation for casodex (bicalutamide) 150 mg in august 2005.
efter egen gennemgang af disse oplysninger i 2004 og som følge af de resulterende betænkeligheder ved risk/ benefit- forholdet for bicalutamid 150 mg ved lokalt avanceret prostatacancer suspenderede de belgiske tilsynsmyndigheder i august 2005 den nationale markedsføringstilladelse for casodex (bicalutamid), 150 mg.